Alumis (NASDAQ:ALMS) Insider Jorn Drappa Sells 2,447 Shares

Alumis Inc. (NASDAQ:ALMS) insider Jorn Drappa sold 2,447 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $64,527.39. Following the completion of the sale, the insider owned 56,892 shares of the company’s stock, valued at approximately $1,500,242.04. This represents a 4.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Alumis Stock Performance

ALMS stock opened at $27.12 on Thursday. Alumis Inc. has a 1-year low of $3.76 and a 1-year high of $31.35. The firm has a market cap of $3.46 billion, a PE ratio of -13.70 and a beta of -0.69. The business’s 50-day moving average price is $25.37 and its two-hundred day moving average price is $25.22.

Alumis (NASDAQ:ALMS) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.73) by ($0.01). The business had revenue of $1.74 million during the quarter, compared to the consensus estimate of $2.10 million. Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%. On average, analysts forecast that Alumis Inc. will post -2.87 earnings per share for the current year.

More Alumis News

Here are the key news stories impacting Alumis this week:

• Neutral Sentiment: HC Wainwright reaffirmed its “Neutral” rating on Alumis, indicating the analyst does not currently see a strong enough catalyst to support a more bullish view. HC Wainwright Reaffirms Neutral Rating for Alumis
• Negative Sentiment: Six company insiders, including CFO John R. Schroer, sold a combined 14,953 shares of Alumis on August 3 at an average price of $26.37, generating approximately $394,311 in proceeds. The sales reduced individual holdings by roughly 1.28% to 12.28%; the CFO’s position declined 11.72%. While insider sales can reflect personal financial planning rather than a change in business outlook, the concentration of sales may weigh on investor sentiment. The transactions were reported in SEC filings for Read More., Read More., Read More., Read More., Read More., and Read More..

Wall Street Analyst Weigh In

ALMS has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Alumis in a research note on Tuesday, July 7th. Guggenheim increased their price objective on shares of Alumis from $32.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, May 15th. Wall Street Zen lowered shares of Alumis from a “hold” rating to a “sell” rating in a report on Saturday, May 16th. Chardan Capital boosted their price objective on shares of Alumis from $38.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, May 19th. Finally, Wells Fargo & Company upped their target price on shares of Alumis from $49.00 to $51.00 and gave the stock an “overweight” rating in a research note on Friday, May 15th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.30.

Hedge Funds Weigh In On Alumis

Several hedge funds have recently made changes to their positions in the business. MPM Bioimpact LLC bought a new position in Alumis in the fourth quarter valued at $23,443,000. Janus Henderson Group PLC acquired a new position in shares of Alumis during the 1st quarter worth about $46,790,000. Orbimed Advisors LLC acquired a new position in shares of Alumis during the 2nd quarter worth about $5,779,000. Woodline Partners LP grew its holdings in shares of Alumis by 809.7% in the 3rd quarter. Woodline Partners LP now owns 1,751,150 shares of the company’s stock valued at $6,987,000 after acquiring an additional 1,558,660 shares in the last quarter. Finally, Samsara Biocapital LLC grew its holdings in shares of Alumis by 47.0% in the 2nd quarter. Samsara Biocapital LLC now owns 4,801,370 shares of the company’s stock valued at $14,404,000 after acquiring an additional 1,534,872 shares in the last quarter.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.